Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy

NCT04745559 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large-Cell Lymphoma
Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Transformed Follicular Lymphoma (TFL)
High-grade B-cell Lymphoma (HGBCL)
Follicular Lymphoma

Interventions

BIOLOGICAL: Pneumococcal conjugate vaccine (PCV13)
BIOLOGICAL: CD19 targeted CAR T Cell Therapy

Sponsor

H. Lee Moffitt Cancer Center and Research Institute